§ 02 · Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇪🇬Egypt No fee amount confirmed	🇪🇺European Union Fees verified 12 September 2026
Authority & dossier
Fee confirmation	No fee amount confirmed	Fees verified 12 September 2026
Regulatory authority	EDA	EMA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	Available
Reference agencies	FDA (US), EMA, MHRA (UK), Health Canada +4	Not stated
Lead pathway (timeline & fees), New Drug Registration, Standard Review · Centralised Procedure
Pathway name	New Drug Registration, Standard Review	Centralised Procedure
Approval timeline	365-730 days	210-277 days
Headline fee and pathway	Fees not covered	EUR 865,200, Centralised Procedureconditional on other
Recurring charges	Fees not covered	EUR 232,400 a year, per marketing authorisation, other applications
Local representative	Required	Required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	Yes
Local responsible person	Yes	Yes
RP role	MAHs must designate a Qualified Person responsible for the licensed premises (typically a registered pharmacist), and a Qualified Person for Pharmacovigilance (QPPV) as the contact for the Egyptian Pharmacovigilance Centre (EPVC) within EDA.	Qualified Person Responsible for Pharmacovigilance (QPPV), must reside and operate in the EU/EEA, is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).
Accelerated pathways
Designations available	3 designations	6 designations
Examples	Reliance / Verification, Expedited Pathway, Emergency Use Authorisation (EUA), Conditional Registration / Compassionate Use Programme	Accelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3
Post-approval lifecycle
Variations framework	Variations are classified per EDA variation guidelines (aligned with EU variation classification) into Type IA / IAIN (notification), Type IB (minor, prior approval), Type II (major, prior approval) and Extensions. EDA aligned its variations framework with EU practice as part of its ML3 work.	Commission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor, Do and Tell, 12-month notification), Type IAIN (minor, immediate notification), Type IB (minor, Tell, Wait, and Do, 30-day default), Type II (major, prior approval, 60 to 90 days), and Extensions (Annex I changes, full review). Worksharing procedures consolidate variations across multiple authorisations.
Renewal cycle	Drug Registration Certificate is initially valid for 10 years (from 2019 reform, replacing the prior 5-year cycle) and renewable for 10 years; renewal requires up-to-date CMC, safety, GMP and labelling information.	Initial 5-year renewal, application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.
Pharmacovigilance	The Egyptian Pharmacovigilance Centre (EPVC) within EDA coordinates national ADR reporting; Egypt is a member of the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre). MAHs must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances and vaccines.	Comprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	60-120 days	60-106 days
GCP standard	ICH E6(R2) GCP; Egyptian Clinical Trials Law No. 214/2020 and EDA GCP guidelines; Helsinki Declaration	ICH E6(R3), Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025
Pricing & reimbursement
Price regulation	Regulated	Regulated
Reference pricing	Yes	Yes
HTA required	No	Yes
HTA body	No formal national HTA agency; HTA capacity is being developed within EDA and the General Authority for Healthcare Accreditation and Regulation (GAHAR) under the UHI reforms.	EU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)

Verdict colours indicate lower, moderate, or higher regulatory burden, they're not value judgements on a market.

Authority & dossier

Fee confirmation

EgyptNo fee amount confirmed
European UnionFees verified 12 September 2026

Regulatory authority

EgyptEDA
European UnionEMA

English submissions

EgyptYes
European UnionYes

CTD accepted

EgyptYes
European UnionYes

eCTD accepted

EgyptYes
European UnionYes

Reliance pathway

EgyptAvailable
European UnionAvailable

Reference agencies

EgyptFDA (US), EMA, MHRA (UK), Health Canada +4
European UnionNot stated

Lead pathway (timeline & fees), New Drug Registration, Standard Review · Centralised Procedure

Pathway name

EgyptNew Drug Registration, Standard Review
European UnionCentralised Procedure

Approval timeline

Egypt365-730 days
European Union210-277 days

Headline fee and pathway

EgyptFees not covered
European UnionEUR 865,200, Centralised Procedureconditional on other

Recurring charges

EgyptFees not covered
European UnionEUR 232,400 a year, per marketing authorisation, other applications

Local representative

EgyptRequired
European UnionRequired

Local manufacturing

EgyptNot required
European UnionNot required

GMP inspection

EgyptRequired
European UnionRequired

MAH & local presence

Local entity required

EgyptYes
European UnionYes

Local responsible person

EgyptYes
European UnionYes

RP role

EgyptMAHs must designate a Qualified Person responsible for the licensed premises (typically a registered pharmacist), and a Qualified Person for Pharmacovigilance (QPPV) as the contact for the Egyptian Pharmacovigilance Centre (EPVC) within EDA.
European UnionQualified Person Responsible for Pharmacovigilance (QPPV), must reside and operate in the EU/EEA, is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).

Accelerated pathways

Designations available

Egypt3 designations
European Union6 designations

Examples

EgyptReliance / Verification, Expedited Pathway, Emergency Use Authorisation (EUA), Conditional Registration / Compassionate Use Programme
European UnionAccelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3

Post-approval lifecycle

Variations framework

EgyptVariations are classified per EDA variation guidelines (aligned with EU variation classification) into Type IA / IAIN (notification), Type IB (minor, prior approval), Type II (major, prior approval) and Extensions. EDA aligned its variations framework with EU practice as part of its ML3 work.
European UnionCommission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor, Do and Tell, 12-month notification), Type IAIN (minor, immediate notification), Type IB (minor, Tell, Wait, and Do, 30-day default), Type II (major, prior approval, 60 to 90 days), and Extensions (Annex I changes, full review). Worksharing procedures consolidate variations across multiple authorisations.

Renewal cycle

EgyptDrug Registration Certificate is initially valid for 10 years (from 2019 reform, replacing the prior 5-year cycle) and renewable for 10 years; renewal requires up-to-date CMC, safety, GMP and labelling information.
European UnionInitial 5-year renewal, application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.

Pharmacovigilance

EgyptThe Egyptian Pharmacovigilance Centre (EPVC) within EDA coordinates national ADR reporting; Egypt is a member of the WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre). MAHs must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances and vaccines.
European UnionComprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.

Unlicensed access

Named Patient Supply

EgyptAvailable
European UnionAvailable

Compassionate Use

EgyptAvailable
European UnionAvailable

Emergency Import

EgyptAvailable
European UnionAvailable

Parallel Import

EgyptNot permitted
European UnionPermitted

Clinical trials

CTA approval

EgyptRequired
European UnionRequired

Ethics approval

EgyptYes
European UnionYes

CTA timeline

Egypt60-120 days
European Union60-106 days

GCP standard

EgyptICH E6(R2) GCP; Egyptian Clinical Trials Law No. 214/2020 and EDA GCP guidelines; Helsinki Declaration
European UnionICH E6(R3), Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025

Pricing & reimbursement

Price regulation

EgyptRegulated
European UnionRegulated

Reference pricing

EgyptYes
European UnionYes

HTA required

EgyptNo
European UnionYes

HTA body

EgyptNo formal national HTA agency; HTA capacity is being developed within EDA and the General Authority for Healthcare Accreditation and Regulation (GAHAR) under the UHI reforms.
European UnionEU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)